MX370491B - Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas. - Google Patents

Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas.

Info

Publication number
MX370491B
MX370491B MX2015008977A MX2015008977A MX370491B MX 370491 B MX370491 B MX 370491B MX 2015008977 A MX2015008977 A MX 2015008977A MX 2015008977 A MX2015008977 A MX 2015008977A MX 370491 B MX370491 B MX 370491B
Authority
MX
Mexico
Prior art keywords
alkyl
protein misfolding
aryl
treatment
therapeutic use
Prior art date
Application number
MX2015008977A
Other languages
English (en)
Spanish (es)
Other versions
MX2015008977A (es
Inventor
Bertolotti Anne
Guedat Philippe
Original Assignee
Inflectis Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflectis Bioscience filed Critical Inflectis Bioscience
Publication of MX2015008977A publication Critical patent/MX2015008977A/es
Publication of MX370491B publication Critical patent/MX370491B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2015008977A 2013-01-10 2014-01-10 Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas. MX370491B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (2)

Publication Number Publication Date
MX2015008977A MX2015008977A (es) 2016-05-16
MX370491B true MX370491B (es) 2019-12-16

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008977A MX370491B (es) 2013-01-10 2014-01-10 Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas.

Country Status (21)

Country Link
US (4) US9682943B2 (enExample)
EP (2) EP3115357B1 (enExample)
JP (1) JP6276289B2 (enExample)
KR (1) KR102166665B1 (enExample)
CN (1) CN105189452B (enExample)
AU (2) AU2014204831C1 (enExample)
CA (1) CA2896976C (enExample)
DK (1) DK2943467T3 (enExample)
ES (2) ES2831453T3 (enExample)
GB (1) GB201300435D0 (enExample)
HR (1) HRP20161208T1 (enExample)
HU (1) HUE030848T2 (enExample)
IL (1) IL239629B (enExample)
LT (1) LT2943467T (enExample)
MX (1) MX370491B (enExample)
PL (1) PL2943467T3 (enExample)
PT (1) PT2943467T (enExample)
RS (1) RS55185B1 (enExample)
RU (1) RU2654910C2 (enExample)
SI (1) SI2943467T1 (enExample)
WO (1) WO2014108520A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
CA2951191C (en) 2014-07-02 2022-09-13 Inflectis Bioscience Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
DK3280404T3 (da) 2015-04-08 2021-11-08 Res & Innovation Uk Fremgangsmåder til valg af phosphatase-selektive og ikke-selektive phosphatasehæmmere
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
AU2016304331B2 (en) * 2015-07-31 2021-08-05 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
WO2019215470A1 (en) 2018-05-09 2019-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
KR20250157531A (ko) * 2023-03-16 2025-11-04 교토후고리츠다이가쿠호진 Ampk 활성화 및/또는 chop 억제에 의한 치료가 가능한 질환 및 장애의 치료를 위한 sephin1 및 관련 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223492A (en) 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2001025192A1 (en) 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
KR20060088885A (ko) * 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 뉴로펩티드 ff 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
EP1908465B1 (en) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating prion-based diseases
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
US20120202814A1 (en) 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
US9321735B2 (en) 2010-07-20 2016-04-26 Vestaron Corporation Insecticidal triazines and pyrimidines
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Also Published As

Publication number Publication date
US10100020B2 (en) 2018-10-16
EP3115357A1 (en) 2017-01-11
CA2896976C (en) 2021-03-02
EP2943467A1 (en) 2015-11-18
US10954198B2 (en) 2021-03-23
AU2014204831A1 (en) 2015-07-23
US20200095210A1 (en) 2020-03-26
AU2017272151B2 (en) 2018-11-08
BR112015016433A2 (pt) 2017-07-11
PL2943467T3 (pl) 2017-01-31
IL239629A0 (en) 2015-08-31
CN105189452A (zh) 2015-12-23
CA2896976A1 (en) 2014-07-17
ES2594378T3 (es) 2016-12-19
US9682943B2 (en) 2017-06-20
US20180354914A1 (en) 2018-12-13
JP6276289B2 (ja) 2018-02-07
EP2943467B1 (en) 2016-07-13
RU2015127827A (ru) 2017-01-12
RU2654910C2 (ru) 2018-05-25
PT2943467T (pt) 2016-10-18
ES2831453T3 (es) 2021-06-08
CN105189452B (zh) 2018-12-18
LT2943467T (lt) 2016-10-10
KR102166665B1 (ko) 2020-10-16
IL239629B (en) 2018-03-29
AU2014204831C1 (en) 2018-04-05
WO2014108520A1 (en) 2014-07-17
SI2943467T1 (sl) 2016-11-30
RS55185B1 (sr) 2017-01-31
DK2943467T3 (en) 2016-10-03
KR20150127574A (ko) 2015-11-17
US20160046589A1 (en) 2016-02-18
AU2017272151A1 (en) 2017-12-21
AU2014204831B2 (en) 2017-09-07
GB201300435D0 (en) 2013-02-27
HUE030848T2 (hu) 2017-06-28
JP2016504400A (ja) 2016-02-12
US20170247344A1 (en) 2017-08-31
MX2015008977A (es) 2016-05-16
HRP20161208T1 (hr) 2016-11-04
EP3115357B1 (en) 2020-08-12
US10526297B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
MX370491B (es) Derivados de bencilidenguanidina y uso terapeutico para tratamiento de enfermedades causadas por proteinas mal plegadas.
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
AR095347A1 (es) Compuestos orgánicos
JOP20190070B1 (ar) مركبات بنزو[b] ثيوفين كناهضات محفزة لبروتين جينات الإنترفيرون
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
MX387984B (es) Inhibidor del egfr y preparación y aplicación del mismo.
PH12014501719A1 (en) Pyridone derivatives
MX391812B (es) Agonista fxr derivado de esteroides.
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
EA201690752A1 (ru) Ингибиторы g12c kras
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
NZ712207A (en) Tetrahydropyrrolothiazine compounds
CY1120420T1 (el) Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης
MX2013003507A (es) Proceso de elaboracion para derivados de pirimidina.
EA201491820A1 (ru) Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения
CY1119289T1 (el) Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
EA201690763A1 (ru) Лечение рака поджелудочной железы
MX2015015614A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con el receptor del retinoide (rorc).

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: INFLECTIS BIOSCIENCE

FG Grant or registration